The company is developing hyaluronic acid products for surgical and therapeutic applications. * Cangene Corp., of Toronto, received approval to sell WinRho SD in Canada for immune thrombocytopenic purpura...It is being developed with Pfizer Inc., of New York. * PerSeptive Biosystems Inc., of Framingham, Mass., said shareholders approved the issuance of stock for the acquisition of PerSeptive Technologies II Corp., which was formed in 1993 and contracted with PerSeptive to conduct research and

A phase III study is expected to begin later this year. * Sparta Pharmaceuticals Inc., of Research Triangle Park, N.C., agreed to issue 2.6 million shares to takeover Lexin Pharmaceutical Corp., of Horsham, Pa...The acquisition is expected to close by the end of March 1996

The study, expected to take up to year, will be conducted in Switzerland...Multikine is a combination of interleukin-2 and other cytokines. * Genzyme Transgenics Corp., of Framingham, Mass., said it signed agreements with two biopharmaceutical firms to provide preclinical testing services

The study, expected to take up to year, will be conducted in Switzerland...Both partnerships are expected to generate $2 million a year

The bioresorbable membrane is designed to prevent internal adhesions following abdominal and pelvic surgeries. * Sparta Pharmaceuticals Inc., of Research Triangle Park, N.C., agreed to issue 2.6 million shares to takeover Lexin Pharmaceutical Corp., of Horsham, Pa...The acquisition is expected to close by the end of March 1996

The hand-held device is designed to allow patients to self-administer pain medication. * Hybridon Inc., of Worcester, Mass., and its partner, Pharmacia Biotech AB, of Uppsala, Sweden, said they have synthesized commercial quantities of their antisense AIDS drug, GEM 91, at a fraction of what it used to cost to produce oligonucleotide compounds

LLC, of New York, have options to buy another 330,000 shares to cover overallotments. * Quintiles Transnational Corp., of Research Triangle Park, N.C., completed its acquisition of PMC Contract Research AB, of Uppsala, Sweden...Quintiles issued 273,000 shares and paid $1.3 million in cash for the takeover. * T Cell Sciences Inc., of Needham, Mass., said results from a Phase I trial of TP10, which is a complement inhibitor, showed the compound was well-tolerated and the amount detected in the

The study is expected to be complete by the end of March 1996 and results should be available within the following three months. * MedImmune Inc., of Gaithersburg, Md., boosted the funding from its 3 million share follow-on offering to $62 million with the sale of an additional 450,000 shares to the underwriters to cover overallotments

The product is intended for use by blood and plasma collection centers to screen for HIV...Geron Corp., of Menlo Park, Calif., and Dianon Systems Inc., of Stratford, Conn., entered into a technology development agreement to explore telomerase detection as a cancer diagnostic technology

Repligen previously had an agreement to sell Allegro to Apotex U.S.A. Inc., a New York affiliate of Toronto-based Apotex Inc. * OncoRx Inc., of New Haven, Conn., changed its name to VION Pharmaceuticals Inc

LLC, of New York, have an option to purchase 360,000 additional shares to cover overallotments. * Osteotech Inc., of Eatontown, N.J., adopted a shareholder rights plan against hostile takeovers...The company now owns worldwide rights to the drug. * Scios Nova Inc., of Mountain View, Calif., said basic fibroblast growth factor (bFGF) reduced brain injury in experimentally induced stroke in animal models...Three other trials are testing the drug for hemorrhagic trauma, meningococcemia and partial

The company registered to sell the shares in December 1995. (See BioWorld Today, Dec. 28, 1995, p. 1.) * ESCAgenetics Corp., of San Carlos, Calif., and two subsidiaries _ PHYTOpharmaceuticals Inc...Great Fund also agreed to make an equity investment of up to $8 million later this year and it received an option to purchase up to 80 percent of Ryan Pharmaceuticals Inc., a subsidiary of Receptagen, for $7 million. * Rhone-Poulenc Rorer Inc., of Collegeville, Pa., said the Czech Republic approved

Advanced Tissue said it expects to file the PMA in late 1996...Pioneer intends to use the information to boost agronomic performance of corn crops and develop pest resistance. * Neurogen Corp., of Branford, Conn., said it developed a drug discovery technology for use with its combinatorial chemistry

signed a licensing agreement with the government of Israel to commercialize oligosaccharide elicitors, compounds that elicit immune responses from plants. * Novo Nordisk A/S, of Bagsvaerd, Denmark, and Bio-Intermediair, of Groningen, Netherlands, entered into a manufacturing agreement for the production of monoclonal antibodies...Bio-Intermediair also recently broke ground on a $C35 million manufacturing facility in Montreal. * Oxford Asymmetry, of Oxford, U.K., which specializes in the

Also, Metra entered into a definitive agreement to acquire Osteo Sciences Corp...It's Sugen's first extension into dermatology. * Texas Biotechnology Corp., of Houston, will provide data from its Novastan (brand of argatroban) trials in heparin-induced thrombocytopenia to Synthelabo, of Paris, which will pay Texas Biotechnology up to $2.5 million for the information

Interneuron estimates the cost for the remaining shares to be $7 million to $8 million. * Lidak Pharmaceuticals, of La Jolla, Calif., started two Phase II studies in HIV patients evaluating Lidakol as a topical treatment for Kaposi's sarcoma cutaneous lesions and Molluscum contagiosum. * Procept Inc., of Cambridge, Mass., said Thursday it registered to sell 2.2 million shares in a public offering...Trials of the antibody ultimately are expected to include 130 patients and 20 sites. (c) 1997

Pimagedine is designed to block formation of advanced glycosylation end-products (AGE), whose accumulation has been linked to diabetes and other age-related diseases

The court instructed Cambridge to pay a 1 percent royalty on net sales, and damages equal to 1 percent royalty for the pre-license period...subsidiary, relating to the sale and promotion of its TRAx CD4 and CD8 microtiter plate, an enzyme immunoassay used for enumeration of CD4 T lymphocytes. * Metra Biosystems Inc., of Mountain View, Calif., got U.S

Levitt developed technology to identify genes responsible for controlling bronchial hyperresponsiveness associated with asthma, and at Magainin he will create an asthma research program. * Paracelsian Inc., of Ithaca, N.Y., and the National Cancer Institute entered into a letter of intent to collaborate on Phase I and II studies of Paracelsian's PN355 and related compounds for cancer and HIV...The drugs is designed to block the binding of gp120 to the CD4 protein. * QLT PhotoTherapeutics Inc., of